There last offering was on June 14, 2012. It was 3,400,000 shares of common stock at a price to the public of $14.75. This gave them a net proceeds of $47.3 million, after deducting underwriting discounts and commissions. This should last them more than a year, well into after FDA approval by the end of this year. The facts are all in their Website. Shorties are trying to create fear by lies, longs be aware.
FDA advisers vote 13-2 that Aegerion data sufficient for approval. Experts all agreed that it makes FDA approval pretty much a sure thing. The company has prepared for the approval and the commercialization of their drug for a long time(see their quarterly report) and the sale would be immediate after approval. Cash flow could be quick and strong starting 3 months from now.